OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2022-01-19 15:46:23

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Contagious caprine pleuropneumonia
Address of laboratory:	Campus International de Baillarguet TA A-117/E 34398 Montpellier Cedex 5 FRANCE
Tel.:	+33 (0)4 67 59 37 39
Fax:	
E-mail address:	lucia.manso-silvan@cirad.fr
Website:	http://umr-astre.cirad.fr
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Nathalie Vachiery
Name (including Title and Position) of OIE Reference Expert:	Lucia Manso-Silvan
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CCPP cELISA	Yes	2	2
Direct diagnostic tests		Nationally	Internationally
PCR	Yes	0	2
isolation	Yes	0	2

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Antigen	cELISA	produced	20	0	1	☐Africa ☐Americas ☐Asia and Pacific ☒Europe ☐Middle East
Reference serum	cELISA	produced	10	3	2	☐Africa ☐Americas ☒Asia and Pacific ☒Europe ☐Middle East
DNA	PCR	produced	0	3	1	☐Africa ☐Americas ☐Asia and Pacific ☒Europe ☐Middle East

4. Did your laboratory produce vaccines?

Yes

5. Did your laboratory supply vaccines to OIE Member Countries?

Yes

Vaccine name	Amount supplied nationally (ml, mg) (including for own use)	Amount supplied to other countries (ml, mg)	Name of recipient OIE Member Countries
Mccp saponin inactivated	0	40	JORDAN
Mccp inactivated, in oil adjuvant	0	350	UNITED ARAB EMIRATES

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

Yes

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

Yes

Name of the new test or diagnostic method or vaccine developed	Description and References (Publication, website, etc.)
New qPCR assay	ongoing
Mcc inactivated vaccine	ongoing

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
BURKINA FASO	December 2021	152 (vaccine trial)	0
KENYA	October 2021	430 +107 (vaccine trial)	0

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

No

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
MultiVacc	4 years	improved inactivated vaccines	KALRO, CIRDES, ILRI	KENYA

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Multi-locus typing data of strains from Pakistan and China

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:
ongoing

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 0

b) International conferences: 2
Vicki Chalker, Mitchell Balish, Assunta Bertaccini, Alain Blanchard, Daniel R. Brown, Joachim Frey, Gail Gasparich, Ludwig Hoelzle, Christine Knox, Chih-Horng Kuo, Lucia Manso-Silvan, et al (2021). Mycoplasma taxonomy: what's in a name and where to submit? XXIII Biennial Congress of the International Organization for Mycoplasmology (IOM), November 2021.

Jores J, Baldwin C, Blanchard A, Browning GF, Colston A, Gerdts V, et al. (2021) Contagious Bovine and Caprine Pleuropneumonia: a research community's recommendations for the development of better vaccines. XXIII Biennial Congress of the International Organization for Mycoplasmology (IOM), November 2021.

c) National conferences: 0

d) Other:
(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 1
b) Seminars: 0
c) Hands-on training courses: 0
d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
a	Kenya	2

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO17025	1-2207.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
cELISA (flexible)	COFRAC

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

Yes

National/ International	Title of event	Co-organiser	Date (mm/yy)	Location	No. Participants
International	MultiVacc meeting	CIRDES	December 2021	virtual	22

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

No

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report:

In collaboration with the CEA, (Marcoule-FR), the Reference Laboratory at ASTRE implements mass spectrometry (MS) quality control of inactivated CCPP vaccines produced either by us or by other research laboratories, for research or control purposes (cf. Thiaucourt, F., Pible, O., Miotello, G., Nwankpa, N., Armengaud, J., 2018. Improving quality control of Contagious Caprine Pleuropneumonia vaccine with tandem mass spectrometry. PROTEOMICS 0, 1800088).